Patient-reported outcomes provide prognostic information for survival in patients with diffuse large B-cell lymphoma: Analysis of 1239 patients from the GOYA study.
International Prognostic Index
diffuse large B-cell lymphoma
patient-reported outcomes
prognostic factor
survival
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
23
02
2022
received:
02
09
2021
accepted:
08
03
2022
pubmed:
25
3
2022
medline:
15
9
2022
entrez:
24
3
2022
Statut:
ppublish
Résumé
We investigated the prognostic value of pretreatment patient-reported outcomes (PROs) in patients with diffuse large B-cell lymphoma (DLBCL) receiving obinutuzumab/rituximab plus chemotherapy in the GOYA phase III study. Patients completed the European Organization for Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) and the Functional assessment of chronic illness therapy-Lymphoma (FACT-Lym) lymphoma subscale (LYMS) during the study. PRO scales with high prognostic value were identified through Cox regression analyses of overall survival (OS) and progression-free survival (PFS). These scales were evaluated in terms of their additional prognostic value beyond the International Prognostic Index (IPI). A preliminary assessment was performed to evaluate whether the scales provided improved patient-risk stratification beyond IPI. One thousand two hundred and fifty-nine patients with valid pretreatment PRO scales were included in the analyses, and complete pretreatment data were available for 1239/1414 patients (87.6%). Four PRO scales with high prognostic value were identified: FACT-Lym LYMS and EORTC QLQ-C30 physical functioning, global health status/quality of life (QoL), and fatigue. All four scales retained significant prognostic value for OS and PFS after IPI adjustment (all p < 0.05). After adjusting for multiple clinical variables (IPI, cell of origin, BCL2 status, and total metabolic tumor volume), all four scales retained significant prognostic value (all p < 0.05) for OS. Only the EORTC QLQ-C30 physical functioning scale was significant (p < 0.05) for PFS after adjustment for multiple clinical variables. In this large population of patients with DLBCL, pretreatment PROs provided prognostic information for OS and PFS beyond the well-established IPI.
Identifiants
pubmed: 35322932
doi: 10.1002/cam4.4692
pmc: PMC9468432
doi:
Substances chimiques
Rituximab
4F4X42SYQ6
Cyclophosphamide
8N3DW7272P
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3312-3322Informations de copyright
© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Cancer. 2014 Jan 15;120(2):302-11
pubmed: 24127333
Clin Cancer Res. 2016 Aug 1;22(15):3801-9
pubmed: 26936916
J Hematol Oncol. 2020 Jun 6;13(1):71
pubmed: 32505213
Lancet Oncol. 2019 Dec;20(12):e685-e698
pubmed: 31797795
J Clin Oncol. 2008 Mar 10;26(8):1355-63
pubmed: 18227528
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
Blood. 2007 Mar 1;109(5):1857-61
pubmed: 17105812
Crit Rev Oncol Hematol. 2019 Jan;133:1-16
pubmed: 30661646
Value Health. 2021 Feb;24(2):250-267
pubmed: 33518032
J Clin Oncol. 2017 Nov 1;35(31):3529-3537
pubmed: 28796588
Am J Hematol. 2019 May;94(5):604-616
pubmed: 30859597
N Engl J Med. 2002 Jun 20;346(25):1937-47
pubmed: 12075054
Blood. 2015 Jan 1;125(1):22-32
pubmed: 25499448
Cancer. 2018 Mar 15;124(6):1251-1259
pubmed: 29231969
Ann Hematol. 2012 Nov;91(11):1747-56
pubmed: 22739576
Cancer Med. 2022 Sep;11(17):3312-3322
pubmed: 35322932
Oncologist. 2020 Apr;25(4):e722-e732
pubmed: 32297435
Health Qual Life Outcomes. 2009 Dec 23;7:102
pubmed: 20030832
N Engl J Med. 1993 Sep 30;329(14):987-94
pubmed: 8141877
J Clin Oncol. 2010 May 10;28(14):2373-80
pubmed: 20385988